A citation-based method for searching scientific literature

Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, Giorgio Valabrega. Int J Mol Sci 2019
Times Cited: 57







List of co-cited articles
433 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
606
31

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
29

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
141
21


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
21

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
957
19

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
165
17

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
17

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
317
15

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
135
15

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Stephanie Lheureux, Marsela Braunstein, Amit M Oza. CA Cancer J Clin 2019
227
15

Checkpoint inhibitors in ovarian cancer: A review of preclinical data.
David W Doo, Lyse A Norian, Rebecca C Arend. Gynecol Oncol Rep 2019
24
37

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, Emin Tahirovic, Ian S Hagemann, George Coukos. Gynecol Oncol 2012
354
14

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Joyce F Liu, Michael Gordon, Jennifer Veneris, Fadi Braiteh, Ani Balmanoukian, Joseph Paul Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sarkar,[...]. Gynecol Oncol 2019
38
21

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
14


Epithelial ovarian cancer.
Stephanie Lheureux, Charlie Gourley, Ignace Vergote, Amit M Oza. Lancet 2019
335
12

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F Liu, Christina Herold, Kathryn P Gray, Richard T Penson, Neil Horowitz, Panagiotis A Konstantinopoulos, Cesar M Castro, Sarah J Hill, Jennifer Curtis, Weixiu Luo,[...]. JAMA Oncol 2019
52
13

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
12

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, Ken Yamaguchi, Toshihiro Higuchi, Haruhiko Yagi, Kenji Takakura, Nagahiro Minato,[...]. Proc Natl Acad Sci U S A 2007
989
12

Tumor infiltrating lymphocytes in ovarian cancer.
Phillip P Santoiemma, Daniel J Powell. Cancer Biol Ther 2015
138
10

The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.
Galaxia M Rodriguez, Kristianne J C Galpin, Curtis W McCloskey, Barbara C Vanderhyden. Cancers (Basel) 2018
52
11

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
10

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone,[...]. Proc Natl Acad Sci U S A 2005
10

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
904
10

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Liya Ding, Hye-Jung Kim, Qiwei Wang, Michael Kearns, Tao Jiang, Carolynn E Ohlson, Ben B Li, Shaozhen Xie, Joyce F Liu, Elizabeth H Stover,[...]. Cell Rep 2018
159
10

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Anniina Färkkilä, Doga C Gulhan, Julia Casado, Connor A Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro,[...]. Nat Commun 2020
55
10

Robust enumeration of cell subsets from tissue expression profiles.
Aaron M Newman, Chih Long Liu, Michael R Green, Andrew J Gentles, Weiguo Feng, Yue Xu, Chuong D Hoang, Maximilian Diehn, Ash A Alizadeh. Nat Methods 2015
10

Immunotherapy in ovarian cancer.
K Odunsi. Ann Oncol 2017
95
10

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
775
8

Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
51
9

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
8

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
384
8

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Liang Cao, Maria I Harrell, Elizabeth M Swisher, Nicole Houston,[...]. J Clin Oncol 2017
137
8

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
81
8

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Vivian Goodell, Lupe G Salazar, Nicole Urban, Charles W Drescher, Heidi Gray, Ron E Swensen, Martin W McIntosh, Mary L Disis. J Clin Oncol 2006
108
8

Ovarian cancer.
Gordon C Jayson, Elise C Kohn, Henry C Kitchener, Jonathan A Ledermann. Lancet 2014
969
8

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Alexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C Kohn, Christina M Annunziata, Stanley Lipkowitz, Jane B Trepel,[...]. J Immunother Cancer 2019
40
12

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
159
8


Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, Michael W Sill, Daniel J Powell, Heather A Lankes, Michael D Feldman, Oliver Zivanovic, Camille Gunderson, Emily Ko, Cara Mathews,[...]. J Clin Oncol 2020
59
8

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Janos L Tanyi, Sara Bobisse, Eran Ophir, Sandra Tuyaerts, Annalisa Roberti, Raphael Genolet, Petra Baumgartner, Brian J Stevenson, Christian Iseli, Denarda Dangaj,[...]. Sci Transl Med 2018
171
8

Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.
Kelly L Singel, Tiffany R Emmons, Anm Nazmul H Khan, Paul C Mayor, Shichen Shen, Jerry T Wong, Kayla Morrell, Kevin H Eng, Jaron Mark, Richard B Bankert,[...]. JCI Insight 2019
45
11

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Blaise Clarke, Anna V Tinker, Cheng-Han Lee, Subbaya Subramanian, Matt van de Rijn, Dmitry Turbin, Steve Kalloger, Guangming Han, Kathy Ceballos, Mark G Cadungog,[...]. Mod Pathol 2009
186
8

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
337
8

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
304
8


Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
7


Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Marco Greppi, Giovanna Tabellini, Ornella Patrizi, Simona Candiani, Andrea Decensi, Silvia Parolini, Simona Sivori, Silvia Pesce, Laura Paleari, Emanuela Marcenaro. Int J Mol Sci 2019
17
23


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.